AVTX
NASDAQAvalo Therapeutics Inc.
News25/Ratings12
News · 26 weeks870%
2026-04-192026-10-11
Mix2690d
- Other11(42%)
- Insider11(42%)
- SEC Filings4(15%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Lind Kevin Robert4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERSEC Form 4 filed by Director Jain Rita4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERSEC Form 4 filed by Director Philip Ron M4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- PRAvalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)WAYNE, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 101,600 shares of common stock (the "Options") as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Options were granted on September 25, 2026 and have an exerc
- PRAvalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 CongressWAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced a late-breaker oral presentation and poster at the upcoming EADV Congress 2026, to be held in Vienna, Austria from September 30-October 3, 2026. EADV Congress 2026 Presentation Details: Late-Breaker Oral Presentation: Title: Efficacy and Safety of Abdakibart (ABD), a Humanized High Affinity and Potency IgG4 Anti-IL-1β Agent for Treatment of Moderate to Severe Hidradenitis Suppurativa at Week 16; IHS4 Subgroup and Lesion Type ANdT Results of
- INSIDERChief Financial Officer Sullivan Christopher Ryan exercised 12,394 shares at a strike of $9.88 and sold $202,437 worth of shares (12,394 units at $16.33) as part of a pre-agreed trading plan (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Financial Officer Sullivan Christopher Ryan exercised 10,185 shares at a strike of $8.04 and sold $179,457 worth of shares (10,185 units at $17.62) as part of a pre-agreed trading plan (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- PRAvalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)WAYNE, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to six new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 78,000 shares of common stock (the "Options") as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Options were granted on September 2, 2026 and have an exercise
- PRAvalo Therapeutics to Participate in Upcoming Investor ConferencesWAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Cantor Global Healthcare Conference 2026 Fireside ChatSeptember 10, 2026, at 8:00 am ET Morgan Stanley 24th Annual Global Healthcare Conference 1x1 meetings onlySeptember 16, 2026 H.C. Wainwright 28th Annual Global Investment Conference PresentationSeptember 16, 2026, at 8:30 am ET Stifel 2026 Virtual Immunology and Inflammation Forum Fireside ChatSeptember 24, 2026
- INSIDERChief Medical Officer Doyle Mittie exercised 679 shares at a strike of $8.04 and sold $13,580 worth of shares (679 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Financial Officer Sullivan Christopher Ryan sold $1,450,419 worth of shares (72,725 units at $19.94) as part of a pre-agreed trading plan and exercised 71,852 shares at a strike of $9.88, decreasing direct ownership by 2% to 39,900 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Medical Officer Doyle Mittie exercised 1,000 shares at a strike of $12.65 and sold $20,000 worth of shares (1,000 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- INSIDERChief Strategy Officer Riley Jennifer sold $52,012 worth of shares (2,655 units at $19.59), decreasing direct ownership by 7% to 37,041 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Medical Officer Doyle Mittie exercised 679 shares at a strike of $8.04 and sold $13,580 worth of shares (679 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- SECSEC Form SCHEDULE 13G filed by Avalo Therapeutics Inc.SCHEDULE 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- SECSEC Form 10-Q filed by Avalo Therapeutics Inc.10-Q - Avalo Therapeutics, Inc. (0001534120) (Filer)
- SECAvalo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
- PRAvalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business UpdatesPlans to initiate a registrational Phase 3 program evaluating abdakibart in hidradenitis suppurativa (HS) in the first half of 2027Expanded pipeline with AVTX-010, a long-acting next-generation anti-IL-1β antibody, with IND submission planned for the first half of 2027Appointed Ron Philip to the Board of DirectorsCash, cash equivalents and investments of $472.2 million as of June 30, 2026, expected to provide runway into 2029 WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced business updates
- INSIDERChief Medical Officer Doyle Mittie exercised 1,000 shares at a strike of $12.65 and sold $20,000 worth of shares (1,000 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- SECSEC Form EFFECT filed by Avalo Therapeutics Inc.EFFECT - Avalo Therapeutics, Inc. (0001534120) (Filer)
- SECSEC Form 424B3 filed by Avalo Therapeutics Inc.424B3 - Avalo Therapeutics, Inc. (0001534120) (Filer)
AVTX FAQ
6 questionsWhere does AVTX stock trade?
Avalo Therapeutics Inc. (AVTX) is listed on NASDAQ.What sector and industry is AVTX in?
Avalo Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Avalo Therapeutics Inc. go public?
Avalo Therapeutics Inc. (AVTX) completed its IPO in 2015.What are analysts saying about AVTX?
Avalo Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $3800.00 price target on 2026-07-06. Recent price targets range from $2500.00 to $4800.00.What companies are similar to AVTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AVTX side-by-side with any of them on Quantisnow.How can I track AVTX on Quantisnow?
Quantisnow aggregates Avalo Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AVTX to receive live email and push alerts on every new disclosure.